Mirikizumab (Omvoh™) for ulcerative colitis

Organoids as regenerative medicine for inflammatory bowel disease

“…Management with biologics have revolutionized outcomes for patients with IBD. 10 , 22 , 23 However, certain drawbacks, such as immunogenicity (i.e., development of anti-drug antibodies) and the requirement of specialized staff, among others, prompted the introduction of a third generation of drugs based on small molecules, e.g., JAK inhibitors and sphingosine-1-phosphate receptor agonists. 22 , 24 , 25 , 26 , 27 …”